Personalized Therapy Study - Attain Stability Quad Post-Approval Study
← catalyst calendarNCT04024943 · readout ≤ 346 d
Sponsored by Medtronic (industry) · MDT — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,092actual
Sites
115
Countries
France, Greece, Italy +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-08-21 | actual | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Intervention
- Device: Quadripolar LV Lead — also filed as Medtronic CRT-P, Medtronic CRT-D
Primary outcome
what the primary-completion date above is the date OFPercentage of patients without a lead- related event at 5 years post-implant
measured 5 years
Publications
- PMID 39694452 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · MDT's whole pipeline · Catalyst calendar · Every registered study · What changed